




We read with interest the excellent review of
Escherichia coli native valve endocarditis by Micol
et al. [1] . As a group, Enterobacteriaceae are the
most frequent bacterial isolates recovered from
both inpatients and outpatient clinical specimens,
but in the past few years, following increased use
of invasive devices and broad-spectrum antibiot-
ics, E. coli has become less prevalent than Gram-
positive cocci as a cause of nosocomial infection.
However, E. coli remains the most common cause
of nosocomial bacteraemia, usually secondary to
urinary tract infections or respiratory disease.
To supplement the review of Micol et al. [1],
we would like to describe a probable case of
pacemaker-related endocarditis caused by E. coli
following intestinal infection.
A female aged 77 years was admitted to hospital
because of diarrhoea. She had received a definitive
VDD pacemaker because of complete block 1 year
previously, but was otherwise healthy. Her clinical
condition deteriorated, with septic shock necessi-
tating admission to the intensive care unit. E. coli
was isolated from blood cultures, with MICs
(mg ⁄L) of 4 for amoxycillin, <1 for cefotaxime
and <0.25 for ciprofloxacin and ofloxacin. Two
days after commencing treatment with cefotaxime
(2 g ⁄ 6 h), the patient developed fever and anae-
mia. Echocardiography showed images suggest-
ing vegetations attached to the pacemaker lead,
and the pacemaker was therefore exchanged
surgically. Culture of the lead in thioglycolate
broth at 35C for 48 h, and then on Columbia agar
supplemented with sheep blood 5% v ⁄v (Becton
Dickinson BBL, Cockeysville, MD, USA) and
chocolate agar (Becton Dickinson) at 37C, both
in a CO2 10% v ⁄ v enriched atmosphere, yielded
no growth. Treatment with cefotaxime plus
gentamicin for 3 weeks resulted in sterile cultures,
resolution of fever and recovery from anaemia.
The ability of a bacterium to cause infective
endocarditis depends (in addition to its virulence)
on its capacity for adherence to the damaged
endocardial surface. E. coli is often isolated from
cases of bacteraemia, but rarely from cases of
endocarditis, as it is not readily adherent. Two
populations who have been reported to be at risk
for Gram-negative endocarditis are injecting drug-
users and patients with prosthetic valves [2], but
there are no previous reports of cases involving
foreign bodies such as pacemaker leads. Infections
involving implantable electrophysiological car-
diac devices occur at rates of 1–7% [3], but the
majority of such infections are caused by staphy-
lococci. The case described above fulfilled the
modified Duke criteria for diagnosis of infective
endocarditis [4], but was associated with a gastro-
intestinal infection rather than a urinary tract
infection as described by Micol et al. [1]. Although
a single case does not allow significant conclu-
sions, the possibility of such complications in
association with endovascular devices should be
considered, especially in elderly patients.
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What is the place of teicoplanin and
linezolid in the treatment of prosthetic joint
infections?
10.1111/j.1469-0691.2006.01560.x
We read with great interest the recent excellent
review in CMI concerning the management of
infections of osteoarticular prostheses [1]. The
management of prosthetic joint infection has
never been standardised, and this topic suffers
from a lack of scientific evidence concerning
many aspects; however, there are two points on
which we do not fully agree with the author.
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The first point concerns the use of teicoplanin as
first-line therapy for non-documented prosthetic
joint infections. It is suggested that teicoplanin or
vancomycin are appropriate options for the initi-
ation of empirical therapy while cultures are
pending, given the high incidence of methicillin-
resistant staphylococci implicated in prosthetic
joint infections. Although we frequently use teico-
planin as a maintenance treatment in patients
with prosthetic joint infections caused by multire-
sistant Staphylococcus spp. when sepsis is con-
trolled andwhen the teicoplaninMIC is low,we do
not prescribe it as initial empirical therapy for the
following reasons: (i) decreased susceptibility to
glycopeptides among methicillin-resistant Staphy-
lococcus aureus has been documented recently, with
the MIC of teicoplanin being consistently higher
than that of vancomycin [2]; (ii) the emergence of
vancomycin intermediately-resistant S. aureus iso-
lates in Japan, the USA, France, Hong Kong and
Korea, given that most vancomycin intermedi-
ately-resistant isolates are resistant to teicoplanin
[3]; (iii) the fact that a significant proportion of
coagulase-negative staphylococci exhibit resist-
ance to teicoplanin, with MICs of 16–32 mg ⁄L [4];
(iv) the fact that in-vitro studies of the pharmac-
odynamics of teicoplanin against various strains of
Staphylococcus spp. demonstrated no significant
bactericidal effect at 24 h when human pharma-
cokinetics were simulated (6 mg ⁄ kg once-daily at
steady state) [5]; and (v) because clinical studies
evaluating teicoplanin for the treatment of severe
staphylococcal infections report inconsistent
responses compared with flucloxacillin [6] or
vancomycin [7]. For all these reasons, we do not
use teicoplanin for treatment of the acute phase of
prosthetic joint infection, when sepsis must be
controlled rapidly, and when the susceptibility of
the pathogen involved is unknown. However, we
have used teicoplanin frequently as a maintenance
treatment to treat prosthetic joint infections when
sepsis is controlled and when no efficient oral
alternatives are available. We have found this
compound to be very convenient as parenteral
antimicrobial therapy for outpatients because of its
ease of administration and its good tolerancewhen
trough levels are monitored regularly.
The second point that we would like to raise
concerns the role of linezolid in the treatment of
prosthetic joint infections. The review in CMI
proposed linezolid as a ‘first-choice option’ for
methicillin-resistant S. aureus prosthetic joint
infections [1]. Although the pharmacokinetic pro-
file of linezolid (i.e., excellent bioavailability and
significant bone diffusion) [8] makes it an attract-
ive compound for the treatment of prosthetic joint
infections there is an absence of clinical data
concerning its use in this indication, and a
significant risk of haematological side-effects in
patients receiving linezolid for >28 consecutive
days [9,10]. Bearing in mind the length of therapy
usually required for the treatment of prosthetic
joint infections (at least 3 months) [1], linezolid
requires further careful consideration before
being recommended as a first-choice option.
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